hemotune aims to develop a proprietary magnetic nanoparticle technology, the HemoSystem, to allow more selective, efficient, and milder removal of disease-related compounds in patients’ blood. The first clinical translation is applied to treat sepsis.

Project Description

hemotune is developing the HemoSystem, a breakthrough medical device for acute-care blood purification.

The first treatment under development is designed to restore adequate immune function in septic shock. Sepsis is the most severe form of an infection in which the body's own defense reaction damages the body’s tissue and organs, leading to a life-threatening situation. The World Health Organization estimates that around 50 million people worldwide are affected by sepsis every year, causing 11 million deaths, or 20% of all global deaths.

HemoSystem consists of three components: the HemoDevice, a dialysis-machine-like device that performs the treatment; the HemoDisposable, a disposable set containing all tubing and plastic parts that come into direct contact with the blood; and the HemoSorbent, a mixture of magnetic beads – so-called HemoBeads – that are directed against multiple disease-related compounds.

While traditional blood-purification devices use non-specific dialysis filters or adsorber cartridges, the HemoSystem is based on a mixture of nanostructured magnetic beads that contain a magnetic core and specific binding agents that allow them to interact only with selected targets. During treatment, a magnetic filter efficiently removes beads and bound targets before the blood is returned to the patient. This direct application of a mixture of different beads is unique in that it allows for the simultaneous removal of multiple disease-related compounds, which would not be achievable using drugs.

During the tenure at Wyss Zurich, the team, led by Lukas Langenegger, advanced the technology and defined the regulatory strategy for magnetic blood purification as a medical device. The team is continuing development at hemotune AG and preparing a clinical trial aimed at gaining market approval of the HemoSystem for use in sepsis.


hemotune AG

Faculty Mentor

Wendelin Stark

Portrait stark 560

Partners and Funding


  • Gebert Rüf Stiftung
  • EU Horizon 2020
  • Eurostars/Eureka
  • Multiple Innosuisse Projects


  • Occident Group
  • Green Cross Medical Science Inc.
  • Zürcher Kantonalbank
  • VP Venture Partners
  • Hemex
  • Private investors/Family Offices


Series B2 funding

hemotune AG announced the successful closing of a CHF 14 million Series B2 round. Read more.

Achieved ISO 13485 certification for QMS

Won Swiss Accelerator

Awarded the Swiss Accelerator from Innosuisse as a transitional measure for Horizon Europe. Read more.

Wyss Zurich project completion

The project hemotune exits Wyss Zurich and continues its operations in its startup company hemotune AG

hemotune AG awarded by Frost & Sullivan

hemotune earns Frost & Sullivan’s 2022 Europe Technology Innovation Leadership Award in the blood purification technology market

Red Dot Design Award 2022

hemotune wins the Red Dot Award: Design Concept 2022 in Singapore. 

Finalist at the Swiss Economic Award 2022

hemotune is a finalist for the Swiss Economic Award 2022. See the live pitch here.

German Innovation Award 2022

hemotune wins the German Innovation Award 2022 in the category Medical Technologies. Read more.

Series B1 funding

hemotune has raised 7.25 million CHF Series B1 funding with an investment consortium. Read more.

Innosuisse Scale-up Award 2022

hemotune has qualified for the 2nd phase of the Innosuisse Scale-up Programme and receives the Innosuisse Scale-up Programme Award. Read more.

Selected for the Venture Leaders Medtech 2021

hemotune is one of the ten startups that is part of the first Venture Leaders Medtech program. Read more.

hemotune on the Cover of Forbes DACH

hemotune is Top 1 Spin-Off to watch and makes it on the Cover of Forbes DACH. Read the article.

Swiss Technology Award 2020 for hemotune

hemotune wins the Swiss Technology Award 2020 in the "Start up" category.

hemotune raises CHF 5.1 million Series A funding

The startup has closed a CHF 5.1 million Series A funding round with an investment consortium.

hemotune gets supported by the EIT Health

hemotune among 11 startups supported by the EIT health Start-up Rescue Instrument.

hemotune receives grant from Innosuisse

hemotune receives an Innosuisse grant worth CHF 580’000.

Finalist of the De Vigier Award 2018

hemotune is among the 10 finalists of the prestigious De Vigier Award. 

hemotune AG incorporation

The ETH Zurich spin-off hemotune is incorporated. 

hemotune wins Venture Kick

hemotune wins Venture Kick Stage 3 support.

Wyss Zurich Admission

hemotune is accepted as a full project.

Gebert Rüf Stiftung support

hemotune receives support by the Gebert Rüf foundation.

hemotune in the TOP2 of Venture Idea 2016

hemotune is the winner in the category Health & Nutrition at the Venture Idea 2016.

Core Team

Lukas langenegger portrait

Lukas Langenegger

Project Leader & Co-Founder

Carlos mora portrait

Carlos Mora

Project Manager Preclinical & Co-Founder

Do you have a breakthrough project you want us to know about?

We invite you to contact the Wyss Zurich office to discuss your project and start the evaluation process.